Friday, November 20, 2026

Subscribe

NewsEdition DR CongoDR Congo

DR Congo launches trial of experimental Bundibugyo Ebola vaccine as outbreak spreads

A first volunteer in DR Congo has received an experimental vaccine against Bundibugyo Ebola. The trial, launched as the outbreak spreads in the east, must still establish its safety and efficacy.

Diplomatic health meeting in Kinshasa, with papers, translation headsets and small table flags.

A race against time in eastern Congo

In the east of the Democratic Republic of the Congo, the battle against Ebola is no longer being fought only at patients’ bedsides. It is also being fought in the laboratory, between public health urgency and scientific caution. In Bunia, in Ituri, a first volunteer received an experimental vaccine on 24 July 2026, designed to protect against the Bundibugyo strain of the Ebola virus, just as the outbreak continues to spread across several eastern provinces.

This initiative says much about the situation. The DRC, which has faced numerous Ebola outbreaks since 1976, is once again on the front line. This time, the strain involved is Bundibugyo, a variant for which there is currently neither an approved vaccine nor a specific approved treatment. The World Health Organization confirmed the country’s 17th Ebola outbreak in May 2026, after it began in Ituri in the north-east, while the National Institute for Biomedical Research in Kinshasa served as the reference laboratory in identifying the strain.

What the facts show, from Kinshasa to Ituri

The trial launched by the University of Oxford is called BD-Ebov. It is a phase 1 study, an early stage designed primarily to assess the vaccine’s safety, tolerability and immune response in healthy adults. Oxford says 50 volunteers aged 18 to 55 are to be recruited. The vaccine candidate, ChAdOx1 BDBV, is based on the same viral platform as the Oxford-AstraZeneca Covid-19 vaccine. The Serum Institute of India manufactured about 620,000 doses in two weeks and delivered 4,000 investigational doses for the trial.

Funding comes from the Coalition for Epidemic Preparedness Innovations, with an $8.6 million programme to advance vaccines against Bundibugyo. Oxford also says other clinical studies are being prepared with partners, including in Uganda, confirming the cross-border dimension of the response. This is important: the outbreak does not respect administrative borders, and the mobility corridors between Ituri, North Kivu, South Kivu and Uganda remain priority areas for vigilance. The WHO and Africa CDC have also stressed regional cooperation and cross-border surveillance.

The response on the ground remains extensive. As of 26 July 2026, the WHO’s weekly report for the African region recorded 1,481 confirmed cases and 454 deaths linked to Bundibugyo across the DRC and Uganda, as well as one imported case in France, with transmission still active in the provinces of Ituri, North Kivu and South Kivu. The WHO says the outbreak in the DRC has become the largest ever documented for this strain. Between 14 and 21 June, confirmed cases rose from 808 to 1,048, while confirmed deaths increased from 192 to 267, showing the speed of the spread in the east of the country.

Why this vaccine matters, and what it does not yet solve

This first trial is not an immediate remedy. It is a scientific milestone. During an active outbreak, an experimental vaccine does not yet protect communities exposed today; it prepares the tools of tomorrow. The WHO has made clear that the forthcoming data must guide the next stages of development and, later, any possible emergency authorisation or approval. Africa CDC has welcomed the acceleration of research while stressing that equitable access, community trust and regulatory safety must remain central.

For the DRC, the stakes extend beyond Ituri alone. An Ebola outbreak weakens health facilities, disrupts routine care and increases costs for families already facing long distances, insecurity and poor transport. Health authorities have also had to contend with operational challenges flagged by the WHO: high mobility linked to mining activities, insecurity in some localities and frequent population crossings over borders. In this context, every death among health workers, every breakdown in the surveillance chain and every delay in treatment carries a heavy cost.

Kinshasa’s role remains central. It is in the capital that the INRB confirms laboratory results, and many response decisions are coordinated from there. But the impact is felt first in Bunia, Mongbwalu, Rwampara and other affected areas, where teams must build trust, trace contacts, isolate, treat and ensure dignified burials. This is where the difference is measured between a response that is announced and one that is genuinely accepted by communities. The experience of the DRC shows that, when it comes to Ebola, technology is never enough on its own; it must be accompanied by social acceptance and a presence on the ground.

A Congolese issue, but an African one too

The significance of this development extends far beyond the DRC. The outbreak has already led the WHO to declare a public health emergency of international concern, and Africa CDC to classify it as a public health emergency of continental security. In other words, it concerns Central Africa and the Great Lakes region, as well as the member states of the East African Community and SADC, several of which have close commercial and social ties with eastern Congo.

It is also a test of the continent’s ability to turn its accumulated experience with Ebola into practical preparedness tools. Announcements about vaccines, clinical trials and the rapid production of doses show that African research, African institutions and international partners can work faster when they align around a clear priority. But the real verdict will come in the weeks ahead: the course of cases, the safety of health workers, the results of ongoing trials and the authorities’ ability to contain the spread in the most exposed health zones.

For now, the signal is twofold. On the one hand, science is finally advancing against a strain that has long had no specific solution. On the other, the outbreak continues to show that in the DRC, medical innovation only has meaning if it supports a rapid, coordinated and credible response, from Kinshasa to the border provinces. Once again, this is where the balance of power between the virus and public organisation will be decided.

Automatic translation. Original French version

News quiz

Edition DR CongoDR Congo: the news quiz for 14–15 November

5 questions